Faculty Recruitment in Gurukrupa Institute of Pharmacy
Gurukrupa Institute of Pharmacy, Majalgaon established in the year 2015.
Applications are invited for following posts on mail.
In the current pandemic scenario, global supplies of nasopharyngeal (NP) swabs are not dependable resulting in supply chain delays, escalating prices and variable quality. CSIR-National Chemical Laboratory (CSIR-NCL), Pune, has developed an indigenous NP swab for collecting samples from the throat cavity of COVID-19 patients. The need for making available domestic technology for NP swabs was flagged by CSIR to NCL in mid-April.
Researchers from the Indian Institute of Integrative Medicine (IIIM), Jammu, have identified a potent compound that has shown cancer-inhibiting activity in their primary studies on pancreatic cancer. For this compound, they have received Investigational New Drug (IND) approval from the New Drugs Division of the Central Drugs Standard Control Organization (CDSCO). It has been recognized as a potent anti-cancer, New Chemical Entity (NCE) effective against pancreatic cancer after completion of preclinical development and IND submission.
A team of researchers from IIT Madras, Cancer Institute, Sree Balaji Dental College and Hospital, Chennai, and Indian Institute of Science (IISc) Bengaluru have identified a specific microRNA (miRNAs) called ‘miR-155’ that is over-expressed in tongue cancer. MicroRNAs (miRNAs) are small Ribo Nucleic Acid. They are non-coding RNAs involved in the regulation of a variety of biological and pathological processes, including the formation and development of cancer. This finding is important in that molecular strategies can potentially be devised to manipulate miR-155 expression to develop therapeutics for tongue cancer.